CBD is anticonvulsant in many acute animal models, but there are limited data in chronic models. Accounts of dramatic improvements with cannabis-based productswith high CBD:D9-THC (e.g.,>20:1) ratios in the popularpress have sparked a serious interest among epilepsy clinicians in pursuing the rigorous, scientific study of CBD. Initial dose-tolerability and double-blind randomized, controlled studies focusingon target intractable epilepsy populations such as patients with Dravet and Lennox-Gastaut syndromes are being planned.
Link: Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
Year: 2014
DOI: 10.1111/epi.12631
Likely probability of the efficacy of cannabis for treatment of Dravet syndrome according to the results found in this study.
CBD